natgillin/translations-raw huggingface dataset:
Undesirable effects in paediatric patients with juvenile idiopathic arthritis In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in frequency and type to those seen in adult patients. 
Neželeni učinki pri otrocih z juvenilnim idiopatskim artritisom Na splošno so bili neželeni učinki pri otrocih z juvenilnim idiopatskim artritisom po vrsti in pogostnosti podobni tistim pri odraslih.
36 months. 
36 mesecev
(Scoreb) Baseline (Scoreb) Week 52 
(Ocenab) Izhodišče 5,5 (Ocenab) 52. teden 3,0
Paediatric patients weighing 62.5 kg or more can be dosed 25 mg given twice a week or 50 mg given once a week using a fixed-dose pre-filled syringe or pre-filled pen. 
Pediatrični bolniki s telesno maso 62,5 kg ali več lahko prejmejo odmerek 25 mg dvakrat na teden ali odmerek 50 mg enkrat na teden kot fiksni odmerek v napolnjeni injekcijski brizgi ali napolnjenem peresniku.
Multipack: 8 (2 packs of 4) pre-filled syringes Multipack: 24 (6 packs of 4) pre-filled syringes 
Večodmerno pakiranje: 8 (2 pakiranja s po 4) napolnjenimi injekcijskimi brizgami Večodmerno pakiranje: 24 (6 pakiranja s po 4) napolnjenimi injekcijskimi brizgami
Various malignancies have also been reported with use of etanercept, including cancers of the breast, lung, skin and lymph glands (lymphoma). 
Pri uporabi etanercepta so poročali tudi o pojavu različnih malignih obolenj, vključno z rakom dojke, pljuč, kože in bezgavk (limfom).
Additionally, the pharmacokinetics of etanercept in rheumatoid arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar. 
Farmakokinetika etanercepta pri bolnikih z revmatoidnim artritisom, ankilozirajočim spondilitisom in psoriazo v plakih je podobna.
• Do not use the pre-filled syringe if the needle cover is missing or not securely attached. 
• Ne uporabljajte napolnjene injekcijske igle, če manjka pokrovček igle ali če ta ni dobro pritrjen.
In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and radiographic progression in RA patients treated with etanercept alone (25 mg twice weekly), methotrexate alone (7.5 to 20 mg weekly, median dose 20 mg), and the combination of etanercept and methotrexate initiated concurrently were compared in 682 adult patients with active rheumatoid 
V drugi dvojno slepi randomizirani študiji, nadzorovani z učinkovino, so primerjali klinično učinkovitost, varnost in radiografsko napredovanje pri bolnikih z revmatoidnim artritisom, ki so jih zdravili samo z etanerceptom (25 mg 2-krat na teden), samo z metotreksatom (7,5 do 20 mg na teden, mediani odmerek 20 mg) ali z etanerceptom in metotreksatom (s sočasnim začetkom), in sicer pri
• Signs of serious infections (including pneumonia, deep skin infections, joint infections and blood infection), such as high fever that may be accompanied by cough, shortness of breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints; 
• znaki resnih okužb (vključno s pljučnico, globokimi okužbami kože, okužbami sklepov in okužbo krvi), npr. visoka vročina, ki jo lahko spremljajo kašelj, kratka sapa, mrzlica, šibkost ali vroč, rdeč, občutljiv, boleč predel na koži ali sklepih;
Position the pre-filled pen approximately 90 degrees to the skin. 
Napolnjen injekcijski peresnik nastavite na kožo pod kotom približno 90 stopinj.
Doses of 10 mg or 25 mg etanercept were administered subcutaneously (SC) twice a week for up to 24 months. 
Odmerki 10 mg ali 25 mg etanercepta so bili dani subkutano (s.c.) 2-krat tedensko do 24 mesecev.
• Allergic reactions: If you or the child experience allergic reactions such as chest tightness, wheezing, dizziness or rash, do not inject more Benepali, and contact your doctor immediately. 
• Alergijske reakcije: Če se pri vas ali otroku pojavi alergijska reakcija, npr. tiščanje v prsnem košu, piskajoče dihanje, omotica ali izpuščaj, prenehajte injicirati zdravilo Benepali in nemudoma obvestite zdravnika.
No studies on the effects on the ability to drive and use machines have been performed. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Študij o vplivu na sposobnost vožnje in upravljanja strojev niso izvedli.
The efficacy of etanercept was compared to methotrexate in a randomised, active-controlled study with blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid arthritis (< 3 years duration) who had never received treatment with methotrexate. 
V randomizirani študiji, nadzorovani z učinkovino, so s slepo radiografsko oceno kot primarnim opazovanim dogodkom primerjali učinkovitost etanercepta z učinkovitostjo metotreksata pri 632 odraslih bolnikih z aktivnim revmatoidnim artritisom (trajanje bolezni manj kot 3 leta), ki se pred tem nikoli niso zdravili z metotreksatom.
There is generally no applicable use of etanercept in children aged below 6 years in the indication plaque psoriasis. 
Etanercepta se običajno ne uporablja za zdravljenje psoriaze v plakih pri otrocih, mlajših od 6 let.
Discontinuation of treatment should be considered in patients who show no response after 4 months. 
Pri bolnikih, ki po 4 mesecih zdravljenja ne pokažejo odziva, je treba razmisliti o prekinitvi zdravljenja.
If re-treatment with Benepali is indicated, the above guidance on treatment duration should be followed. 
Če je indicirano ponovno zdravljenje z zdravilom Benepali, se ravnamo po zgornjih smernicah glede trajanja zdravljenja.
Patients in this study received a dose of 50 mg etanercept or placebo once weekly for 12 weeks and then all patients received open-label 50 mg etanercept once weekly for an additional 12 weeks. 
Bolniki v tej študiji so dobivali odmerek 50 mg etanercepta ali placebo enkrat na teden 12 tednov, potem pa so vsi bolniki v odprtem delu dobivali 50 mg etanercepta enkrat na teden dodatnih 12 tednov.
Benepali is supplied as a solution for injection in a pre-filled pen (solution for injection). 
Zdravilo Benepali je na voljo kot raztopina za injiciranje v napolnjenem injekcijskem peresniku (raztopina za injiciranje).
With twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high as those observed after single doses. 
Pričakovati je, da bodo koncentracije v stanju dinamičnega ravnovesja po odmerjanju 2-krat tedensko približno dvakrat večje od tistih, ki jih izmerimo po enkratnem odmerku.
Your doctor will determine if Benepali is an appropriate treatment. 
Zdravnik bo presodil o primernosti zdravljenja z zdravilom Benepali.
At 24 weeks, 56% of patients in the etanercept-treated group had achieved the PASI 75 compared to 5% of placebotreated patients. 
V 24. tednu je 56 % bolnikov doseglo PASI 75 v skupini, zdravljeni z etanerceptom, v skupini s placebom pa 5 % bolnikov.
Pairwise comparison p-values: † = p < 0.05 for comparisons of etanercept + methotrexate vs. methotrexate and Φ = p < 0.05 for comparisons of etanercept + methotrexate vs. etanercept. 
Vrednosti p za primerjavo po parih: † = p < 0,05 za primerjavo kombinacije etanercepta + metotreksata z metotreksatom in Φ = p < 0,05 za primerjavo kombinacije etanercepta + metotreksata z etanerceptom:
• Material to remind healthcare professionals that Benepali is not for use in children and adolescents who weigh less than 62.5 kg 
• Gradivo, s katerim se zdravstvene delavce opominja, da zdravilo Benepali ni za uporabo pri otrocih in mladostnikih s telesno maso manj kot 62,5 kg.
- The other ingredients are sucrose, sodium chloride, sodium dihydrogen phosphate monohydrate, 
- Druge sestavine zdravila so saharoza, natrijev klorid, natrijev dihidrogenfosfat monohidrat,
Solution for injection 
raztopina za injiciranje
Clear glass (type I) pre-filled syringe with stainless steel needle, rubber needle cover and rubber plunger containing 0.51 ml of solution. 
Napolnjena injekcijska brizga iz prozornega stekla (tipa I) z iglo iz nerjavečega jekla, gumijastim pokrovčkom igle in gumijastim batom, ki vsebuje 0,51 ml raztopine.
• Vaccinations: Some vaccines, such as oral polio vaccine, should not be given during Benepali therapy. 
• Cepljenja: Med zdravljenjem z zdravilom Benepali nekaterih cepiv, npr. peroralnega cepiva proti otroški paralizi, ni dovoljeno uporabljati.
At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients receiving etanercept. 
Pri bolnikih, ki so prejemali etanercept, je po 12 tednih prišlo do statistično pomembnega izboljšanja rezultata SPARCC (SPARCC - Spondyloarthritis Research Consortium of Canada; Kanadski konzorcij za raziskovanje spondilartritisa) za sakroiliakalni sklep (SIJ - Sacroiliac Joint), ki so ga merili z magnetnoresonančnim slikanjem.
Adjusted mean change from baseline was 3.8 for etanercept treated (n = 95) versus 0.8 for placebo treated (n = 105) patients (p < 0.001). 
Prilagojena povprečna sprememba od izhodišča je bila 3,8 pri bolnikih, zdravljenih z etanerceptom (n = 95), in 0,8 pri bolnikih, ki so prejemali placebo
A higher rate of major birth defects was observed in an observational study comparing pregnancies exposed to etanercept (n=370) during the first trimester, with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds ratio 2.4, 95% CI: 1.0-5.5). 
V 1 opazovalni študiji, kjer so primerjali nosečnosti, izpostavljene etanerceptu (n = 370) v prvem trimesečju, z nosečnostmi, ki niso bile izpostavljene etanerceptu ali drugim antagonistom TNF (n = 164), so opazili večji delež resnih prirojenih napak (prilagojeno razmerje obetov 2,4, 95-% IZ: 1,0-5,5).
• Do not inject into areas that are red, hard, bruised, or tender. 
• Ne injicirajte v predele, ki so pordeli, trdi, imajo modrico ali so občutljivi.
Before injection, Benepali single-use pre-filled syringe should be allowed to reach room temperature (approximately 30 minutes). 
Pred injiciranjem je treba počakati, da se napolnjena injekcijska brizga zdravila Benepali za enkratno uporabo segreje na sobno temperaturo (približno 30 minut).
• Do not inject into scars or stretch marks. 
• Ne injicirajte v brazgotine ali strije.
Solid and haematopoietic malignancies (excluding skin cancers) Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been received in the postmarketing period (see section 4.8). 
Čvrste in hematopoetične maligne bolezni (razen kožnega raka) V obdobju trženja zdravila so prejeli več poročil o raznih malignih boleznih (vključno z rakom dojke in pljuč ter limfomi) (glejte poglavje 4.8).
Your doctor may decide to continue to monitor you or the child for the presence of infections after you stop using Benepali. 
Vaš zdravnik se bo morda odločil, da bo vas ali vašega otroka tudi po koncu zdravljenja z zdravilom Benepali spremljal glede prisotnosti okužb.
Benepali is only available as 25 mg pre-filled syringe, 50 mg pre-filled syringe and 50 mg pre-filled pen. 
Zdravilo Benepali je na voljo v obliki 25 mg napolnjene injekcijske brizge, 50 mg napolnjene injekcijske brizge in 50 mg napolnjenega injekcijskega peresnika.
Doses of 25 mg of etanercept (based on dose-finding studies in patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6 months. 
Odmerke etanercepta po 25 mg (na podlagi študij za ugotovitev odmerkov pri bolnikih z revmatoidnim artritisom) ali placebo so dajali subkutano dvakrat na teden 6 mesecev.
Paediatric patients with juvenile idiopathic arthritis In a polyarticular-course juvenile idiopathic arthritis trial with etanercept, 69 patients (aged 4 to 17 years) were administered 0.4 mg etanercept/kg twice weekly for three months. 
Pediatrični bolniki z juvenilnim idiopatskim artritisom V kliničnem preskušanju etanercepta pri 69 bolnikih s poliartikularnim potekom juvenilnega idiopatskega artritisa, starih od 4 do 17 let, so injicirali 0,4 mg etanercepta/kg 2-krat tedensko v obdobju treh mesecev.
In part 1, all patients received 0.4 mg/kg (maximum 25 mg per dose) etanercept subcutaneously twice weekly. 
V prvem delu študije so vsi bolniki 2-krat tedensko prejemali po 0,4 mg/kg (največ 25 mg na odmerek) etanercepta subkutano.
Benepali is administered by an injection under the skin (subcutaneous use). 
Zdravilo Benepali se injicira pod kožo (subkutana uporaba).
What Benepali is and what it is used for What you need to know before you use Benepali How to use Benepali 
Kaj je zdravilo Benepali in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Benepali Kako uporabljati zdravilo Benepali Možni neželeni učinki
Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. 
Ankilozirajoči spondilitis Zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, če je bil odziv na konvencionalno zdravljenje nezadosten.
In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady state AUCs were 466 μg × hr/ml and 474 μg × hr/ml for 50 mg etanercept once weekly (n = 154) and 25 mg twice weekly (n = 148), respectively. 
Pri analizi populacijske farmakokinetike pri bolnikih z ankilozirajočim spondilitisom so vrednosti AUC etanercepta v stanju dinamičnega ravnovesja pri uporabi etanercepta v odmerku 50 mg enkrat na teden (n = 154) znašale 466 μg × h/ml, pri uporabi etanercepta v odmerku 25 mg dvakrat na teden (n = 148) pa 474 μg × h/ml.
6 months 
6 mesecev
- This medicine has been prescribed for you or a child in your care. 
- Zdravilo je bilo predpisano vam ali otroku, za katerega skrbite, osebno in ga ne smete dajati drugim.
• Do not use the pre-filled syringe if it has been dropped onto a hard surface. 
• Ne uporabljajte napolnjene injekcijske igle, če je padla na trdo površino.
During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to etanercept. 
Med obdobjem randomiziranega prekinjanja zdravljenja se je recidiv bolezni (izguba odziva PASI 75) pojavil pri pomembno več bolnikih, ki so bili ponovno v skupini s placebom, kot pri bolnikih, ki so bili ponovno v skupini z etanerceptom.
Patients currently on methotrexate therapy (stable for ≥ 2 months) could continue at a stable dose of 
Bolniki, ki so se takrat zdravili z metotreksatom (stabilno odmerjanje ≥ 2 meseca), so lahko nadaljevali s stalnim odmerkom metotreksata ≤ 25 mg/teden.
arthritis of 6 months to 20 years duration (median 5 years) who had a less than satisfactory response to at least 1 disease-modifying antirheumatic drug (DMARD) other than methotrexate. 
682 odraslih bolnikih z aktivnim revmatoidnim artritisom, pri katerih je bolezen trajala od 6 mesecev do 20 let (mediano trajanje 5 let) in pri katerih je bil odziv na najmanj eno od imunomodulirajočih antirevmatičnih zdravil (DMARD), razen metotreksata, manj kot zadovoljiv.
If you are not sure, please talk to your doctor. 
Če ste negotovi, se posvetujte z zdravnikom.
Clear glass (type I) pre-filled syringe with stainless steel needle, rubber needle cover and rubber plunger containing 0.98 ml of solution. 
Napolnjena injekcijska brizga iz prozornega stekla (tipa I) z iglo iz nerjavečega jekla, gumijastim pokrovčkom igle in gumijastim batom, ki vsebuje 0,98 ml raztopine.
Test: 
Preiskava:
Patients in this study received a dose of 25 mg or 50 mg etanercept, or placebo twice a week for 12 weeks and then all patients received open-label 25 mg etanercept twice weekly for an additional 24 weeks. 
Bolniki v tej študiji so dobivali odmerek 25 mg ali 50 mg etanercepta ali placebo dvakrat na teden 12 tednov, potem pa so vsi bolniki v odprtem delu dobivali 25 mg etanercepta dvakrat na teden dodatnih 24 tednov.
If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately. 
Če se med zdravljenjem ali po njem pojavijo simptomi tuberkuloze (na primer trdovraten kašelj, hujšanje, apatija, blaga vročina) ali kakšne druge okužbe, to nemudoma povejte svojemu zdravniku.
Benepali contains the active substance, etanercept. 
Kaj vsebuje zdravilo Benepali - Učinkovina je etanercept.
Clinical Efficacy results at 12 months: Comparison of etanercept vs. methotrexate vs. etanercept in combination with methotrexate in patients with RA of 6 months to 20 years duration 
Rezultati klinične učinkovitosti po 12 mesecih: primerjava med etanerceptom, metotreksatom in kombinacijo enteracepta in metotreksata pri bolnikih z RA, ki je trajal 6 mesecev do 20 let
Physicians should exercise caution when considering the use of Benepali in patients with a history of recurring or chronic infections or with underlying conditions that may predispose patients to infections, such as advanced or poorly controlled diabetes. 
Zdravniki morajo biti zelo previdni, kadar se odločajo za zdravljenje z zdravilom Benepali pri bolnikih s ponavljajočimi se ali kroničnimi okužbami v anamnezi ali z drugimi osnovnimi stanji (kot je na primer napredovala ali neurejena sladkorna bolezen), ki bi lahko povečala dovzetnost bolnikov za okužbe.
3 months 
3 meseci
Patients treated with Benepali should be given the Patient Alert Card. Benepali is available in strengths of 25 and 50 mg. 
Zdravilo Benepali je na voljo v jakostih 25 in 50 mg.
Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal infections, listeriosis and legionellosis, have been reported with the use of etanercept (see section 4.8). 
Pri uporabi etanercepta so poročali o primerih resnih okužb, sepse, tuberkuloze in oportunističnih okužb, vključno z invazivnimi glivičnimi okužbami, listeriozo in legionelozo (glejte poglavje 4.8).
Among patients receiving etanercept, the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly always occurred by 3 months. 
Pri bolnikih na etanerceptu se je klinični odziv običajno pojavil že v prvem ali drugem tednu zdravljenja, skoraj vedno pa je nastopil do 3. meseca.
Benepali treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque psoriasis. 
4.2 Odmerjanje in način uporabe Zdravljenje z zdravilom Benepali lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa, juvenilnega idiopatskega artritisa, psoriatičnega artritisa, ankilozirajočega spondilitisa, radiografsko nezaznavnega aksialnega spondilartritisa, psoriaze v plakih ali pediatrične psoriaze v plakih.
Etanercept crosses the placenta and has been detected in the serum of infants born to female patients treated with etanercept during pregnancy. 
Zaznali so ga v serumu dojenčkov, rojenim bolnicam, ki so se med nosečnostjo zdravile z etanerceptom.
There have been post-marketing reports of worsening of CHF, with and without identifiable precipitating factors, in patients taking etanercept. 
Obstajajo poročila iz obdobja trženja o poslabšanju KSP pri bolnikih, ki jemljejo etanercept, ob prisotnosti dejavnikov, ki bi lahko sprožili takšno poslabšanje, in brez njih.
The possibility exists for TNF-antagonists, including etanercept, to affect host defences against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses. 
Za antagoniste TNF, vključno z etanerceptom, velja, da lahko vplivajo na naravno odpornost bolnika proti okužbam in malignim obolenjem, saj TNF sodeluje pri vnetju in uravnava celični imunski odziv.
• Do not move the pre-filled pen during the injection. 
• Napolnjenega injekcijskega peresnika med injiciranjem ne premikajte.
Month 3 
3. mesec
• Do not remove the needle cover until you are ready to inject. 
•Z igle ne odstranite pokrova, dokler niste pripravljeni na injiciranje.
Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of continued etanercept therapy in patients who do not respond within 3 months of initiating etanercept therapy. 
Pri bolnikih z juvenilnim idiopatskim artritisom, ki se v 3 mesecih po uvedbi zdravljenja z etanerceptom ne odzovejo na zdravljenje, niso izvedli študij za ovrednotenje učinka kontinuiranega zdravljenja z etanerceptom.
• For enthesitis-related arthritis in patients from the age of 12 years and weighing 62.5 kg or more when other widely used treatments have not worked well enough or are not suitable for them. 
• za zdravljenje artritisa, povezanega z entezitisom, pri bolnikih, starejših od 12 let in s telesno maso 62,5 kg ali več, če zdravljenje z običajnimi oblikami zdravljenja ni bilo uspešno ali jih bolniki niso prenašali.
A dose response was seen; results with 10 mg were intermediate between placebo and 25 mg. Etanercept was significantly better than placebo in all components of the ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the ACR response criteria, such as morning stiffness. 
Rezultati za etanercept so bili statistično pomembno boljši od placeba po vseh kriterijih ACR, prav tako pa tudi po tistih merilih aktivnosti revmatoidnega artritisa, ki v kriterije odziva po ACR niso vključeni, na primer jutranja okorelost.
Remove one pre-filled pen from the carton that is stored in the refrigerator and leave at room temperature for at least 30 minutes before injecting. 
Iz zunanje ovojnine odstranite en napolnjen injekcijski peresnik, shranjen v hladilniku, in ga pustite na sobni temperaturi vsaj 30 minut pred injiciranjem.
The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years were generally mild to moderate and consistent with those commonly seen in outpatient paediatric populations. 
starih od 2 do 18 let, so bile na splošno blage do zmerne in skladne s tistimi, ki jih pogosto vidimo pri skupinah ambulantnih pediatričnih bolnikov.
Merkel cell carcinoma (a type of skin cancer); excessive activation of white blood cells associated with inflammation (macrophage activation syndrome); recurrence of hepatitis B (a liver infection); worsening of a condition called dermatomyositis (muscle inflammation and weakness with an accompanying skin rash); Listeria (a bacterial infection). 
• Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov): Karcinom Merklovih celic (vrsta kožnega raka); čezmerna aktivacija belih krvničk, povezanih z vnetjem (sindrom aktivacije makrofagov); ponovitev hepatitisa B (vnetje jeter); poslabšanje stanja, imenovanega dermatomiozitis (vnetje mišic in mišična oslabelost, ki ju spremlja kožni izpuščaj); listerija (bakterijska okužba).
Common to < 1/10 
Pogosti ≥ 1/100 do < 1/10
• moderate or severe psoriasis. 
• zmerno ali hudo luskavico.
Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-antagonists, including etanercept, has been reported. 
Pri bolnikih, ki so kdaj že bili okuženi z virusom hepatitisa B (HBV) in so se zdravili z antagonisti TNF, vključno z etanerceptom, so poročali o reaktivaciji hepatitisa B. Poročila vključujejo tudi reaktivacijo hepatitisa B pri anti-HBc pozitivnih, vendar HBsAg negativnih bolnikih.
For polyarthritis or extended oligoarthritis in patients from the age of 2 years and weighing 62.5 kg or more, or enthesitis-related arthritis or psoriatic arthritis in patients from the age of 12 years and weighing 62.5 kg or more, the usual dose is 25 mg given twice a week or 50 mg given once a week. 
Običajni odmerek za zdravljenje poliartritisa ali razširjenega oligoartritisa pri bolnikih, starejših od 2 let in s telesno maso 62,5 kg ali več, in za zdravljenje artritisa, povezanega z entezitisom, ali psoriatičnega artritisa pri bolnikih, starejših od 12 let s telesno maso 62,5 kg ali več, je 25 mg dvakrat na teden ali 50 mg enkrat na teden.